Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships.
about
Lipopeptide structure determines TLR2 dependent cell activation level.Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptorsLinear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityRobust immune responses elicited by a fully synthetic three-component vaccine.Lipid motif of a bacterial antigen mediates immune responses via TLR2 signaling.Fate of TLR-1/TLR-2 agonist functionalised pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro.Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.Immunotherapy for cancer: synthetic carbohydrate-based vaccines.Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.Immune Response Modulation of Conjugated Agonists with Changing Linker LengthCarbohydrate-based cancer vaccines: target cancer with sugar bullets.TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors.Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.The Interplay between Daptomycin and the Immune System.Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact.Skin-Specific Unsaturated Fatty Acids Boost the Staphylococcus aureus Innate Immune Response.Mycobacterium tuberculosis lipoproteins in virulence and immunity - fighting with a double-edged sword.Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.The Staphylococcus aureus lipoprotein SitC colocalizes with Toll-like receptor 2 (TLR2) in murine keratinocytes and elicits intracellular TLR2 accumulation.Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.Light Guided In-vivo Activation of Innate Immune Cells with Photocaged TLR 2/6 Agonist.Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers.Toll-like receptor 6-independent signaling by diacylated lipopeptides.Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Physicochemical and Biological Analysis of Synthetic Bacterial Lipopeptides
P2860
Q33228861-75DFF2BE-ED61-48D1-93ED-6C47A235639FQ33591916-2694293D-E085-4CE1-B844-D5CDA1549EC6Q33614657-BC3D50D4-97C5-46C9-9576-2CD63A7A85A7Q33721005-00E679F3-E48A-4434-8D83-1B0FB6643A35Q33911347-A7BD5C09-3280-4DA7-8F39-03F8A7AA1ECDQ34960453-319F960C-C305-4154-9FE1-452D6D0ADEECQ35657628-398B366F-7DB4-4862-B8E2-E7067843085CQ35800918-E0C9C820-CFEC-462B-916E-74281CDAF22DQ36801478-22B81B49-23CE-48CD-8219-4D7185001AE4Q37453814-47B6963A-15F4-4A3B-9F19-720C905F19BDQ37552015-076DC636-67D8-4BD9-8043-45B85D601A0EQ37634354-AA883FBF-4FCE-4FFD-8ECF-781E1E103689Q38016342-57B5A51B-499A-46FB-90A0-7509216706A2Q38132733-5E7BC243-D8C4-474A-90FF-95DD584E487EQ38153040-2B98C22B-7D7A-48F9-8FA6-19EE39C7451BQ38191612-52A7F438-AE66-49F3-9370-DEA5BE67B198Q38279548-76F9EA4A-9811-4691-9599-97DF830EEBE0Q38824843-249CDAD6-68B3-4A67-9EE9-D10886C5AF27Q38878969-54CDFF71-C183-4688-8610-712CD1697E8CQ39254744-3466FAA3-8804-4E5F-A222-3FC462762968Q39549229-499DC0A0-A89F-44A0-9FCE-EDE850ECA0B8Q39594793-E54B7310-3BB0-44FE-8BC4-43E147132CC9Q39650206-74AC57BB-C645-4BE1-AD27-A5A1C17F52D5Q39672510-CCF1CC1D-69CC-4EC4-BAA9-B4EFCC5A0C84Q39725736-8F8C2B31-A1E3-478D-A4D6-7C63D2B341CEQ41388766-88A73D71-D4B1-45CC-973B-564712A1793BQ41762712-A131774C-17C9-4466-82FD-42DFCCC6F80CQ45174439-441E7AAA-5291-4DEF-9C22-F3A8E87FC308Q46675904-A7F3FA48-32F4-4C5E-9433-9BDA3780C15EQ47590580-0AC1EAC6-312A-49F1-AC91-2C14D06E17ACQ57372643-97D8EA2C-74E3-43FB-AB05-3BF72E438103
P2860
Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Synthetic lipopeptide adjuvant ...... ucture-activity relationships.
@en
type
label
Synthetic lipopeptide adjuvant ...... ucture-activity relationships.
@en
prefLabel
Synthetic lipopeptide adjuvant ...... ucture-activity relationships.
@en
P2093
P1433
P1476
Synthetic lipopeptide adjuvant ...... ucture-activity relationships.
@en
P2093
Artur J Ulmer
Günther Jung
Karl-Heinz Wiesmüller
Renate Spohn
Roland Brock
Ute Buwitt-Beckmann
P304
P356
10.1016/J.VACCINE.2003.11.074
P407
P577
2004-06-01T00:00:00Z